

ThromboGenics Announces Protocol Amendment to Phase II CIRCLE Trial Evaluating THR-409 (ocriplasmin) in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)

Leuven, 23 December, 2016 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company developing novel medicines for back of the eye disease, with a focus on diabetic eye disease, today announced that the protocol of the Phase II CIRCLE Trial Evaluating Multiple Doses of THR-409 to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) has been amended.

The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.

The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.

Ends

For further information please contact:

ThromboGenics Wouter Piepers, Global Head of Corporate Communications & IR +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	Citigate Dewe Rogerson David Dible/Sylvie Berrebi Tel: +44 20 7282 2867 david.dible@citigatedr.co.uk Sylvie.berrebi@citigatedr.co.uk
---	--

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics is conducting the CIRCLE study, a Phase II clinical trial evaluating multiple doses of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in patients with Non-Proliferative Diabetic Retinopathy (NPDR).

THR-317, a PIGF inhibitor being developed to treat diabetic macular edema, or as a combination therapy with anti-VEGF treatments, is expected to enter the clinic shortly. In addition, THR-149, a plasma kallikrein inhibitor, which has resulted from research collaboration with Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed from Galapagos, are in late stage pre-clinical development.

ThromboGenics pioneered a new drug category of pharmacological vitreolysis with JETREA[®] (ocriplasmin) which is now approved for the treatment of vitreomacular traction in 54 countries worldwide. ThromboGenics is commercializing JETREA[®] via its subsidiary ThromboGenics, Inc. in the US. Alcon (Novartis) commercializes JETREA[®] outside the United States.

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.